Related Experiment Video
Updated: Jun 20, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Anti-angiogenic factor endostatin in osteosarcoma
Hyun-Soo Kim1, Sung-Jig Lim, Yong-Koo Park
1Department of Pathology, School of Medicine, Kyung Hee University, #1 Heoigidong, Dongdaemun-gu, Seoul, Korea.
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|September 25, 2009
Summary
Endostatin (ES), an angiogenesis inhibitor, is upregulated in osteosarcomas (OSAs). Increased ES expression correlates with larger tumor size, higher grade, advanced stage, and metastasis, suggesting its potential as a prognostic marker for OSAs.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Neoplastic neovascularization involves a balance of pro-angiogenic and anti-angiogenic factors.
- Endostatin (ES) is a known potent inhibitor of angiogenesis.
- The expression and clinical significance of Endostatin in osteosarcomas (OSAs) remain largely uninvestigated.
Purpose of the Study:
- To investigate the expression of Endostatin (ES) in osteosarcoma (OSA) tissues.
- To determine the correlation between ES expression and clinicopathologic parameters and patient outcomes in OSAs.
Main Methods:
- Tissue microarrays were constructed from 46 osteosarcoma (OSA) cases.
- Immunohistochemistry was employed to analyze Endostatin (ES) expression.
- Semi-quantitative scoring assessed the proportion of positive tumor cells; 10% positivity defined ES-positive cases.
Main Results:
- Endostatin (ES) expression was detected in the cytoplasm of OSA tumor cells.
- 32.6% (15/46) of the osteosarcoma (OSA) cases were found to be ES-positive.
- ES expression showed a significant positive correlation with tumor size (p=0.011), histologic grade (p=0.034), stage (p=0.025), and distant metastasis (p=0.036).
Conclusions:
- The expression of Endostatin (ES) is increased in osteosarcomas (OSAs).
- Elevated ES expression is associated with adverse clinicopathologic features in OSAs.
- Endostatin (ES) may serve as a valuable prognostic marker for patients diagnosed with osteosarcomas (OSAs).
